Active, not recruitingPhase 1NCT01937468

Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease

Studying Chronic graft versus host disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Dana-Farber Cancer Institute
Principal Investigator
John Koreth, MBBS, DPhil
Dana-Farber Cancer Institute
Intervention
Treg-enriched infusion(other)
Enrollment
25 enrolled
Eligibility
18 years · All sexes
Timeline
20132026

Study locations (2)

Collaborators

Miltenyi Biomedicine GmbH · Iovance Biotherapeutics, Inc. · National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01937468 on ClinicalTrials.gov

Other trials for Chronic graft versus host disease

Additional recruiting or active studies for the same condition.

See all trials for Chronic graft versus host disease

← Back to all trials